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The paper written by the ISPOR’s Patient-Reported Outcomes
(PRO) Task Force, “Use of Existing PRO Instruments and their
Modiﬁcation: Good Research Practices for Evaluating and Docu-
menting Content Validity,” is both an extremely important and
timely contribution to the literature. Demonstrating the content
validity of a PRO measure to the satisfaction of the Food and
Drug Administration’s (FDA’s) Study Endpoint and Label Devel-
opment (SEALD) team appears to be the most common stum-
bling block when requesting that such a measure be allowed to
support drug approvals or label claims. As such, even instru-
ments that are well accepted by clinicians and researchers in a
given therapeutic area, have been used successfully in previous
clinical trials with the same or very similar patient populations,
and are supported by a wealth of quantitative evidence, have not
been deemed acceptable. This perception is based not only on my
own experiences, but also on those of colleagues across various
pharmaceutical, biotechnology, and consulting companies.
Certainly, the paucity of PRO label claims that have been
approved since the release of the draft PRO Guidance [1], as
described in a recent ISPOR poster presentation [2], suggests a
sizeable disconnect between the FDA/SEALD team and those
seeking or attempting to support such claims (e.g., sponsors,
instrument developers, and psychometricians).
The current paper, written collaboratively by the members of
the ISPOR PRO Task Force and reviewed by numerous other
experts in the ﬁeld, describes a rigorous and practical approach
to demonstrating the content validity of a PRO measure. While
the substance of this paper is largely consistent with and clariﬁes
aspects of the draft PRO Guidance, there are also a number of
important points of departure between the two documents.
Perhaps most striking is the deﬁnition of content validity itself.
While the draft PRO Guidance recommends and SEALD has
commonly required that PRO measures include all concepts
important to patients related to the proposed label claim,
Rothman and her colleagues are clearly in agreement with stan-
dard questionnaire-development procedures and psychometric
texts which state that only a representative or “adequate” sam-
pling of these concepts are required for a measure to have content
validity. For example, the draft Guidance deﬁnes content validity
as follows: “being sure the items in the questionnaire cover all
important aspects of the concept from the patient perspective”
[1]. Content validity is deﬁned elsewhere in the literature,
however, as a “sampling from a pool of required content” [3].
Rather than addressing all symptoms or impacts of a condi-
tion or treatment relevant to the proposed label claim, as has
been required to satisfy the FDA recently, including a represen-
tative sample of the potential universe of items in a PRO measure
is both sufﬁciently rigorous and more practical for the purpose of
clinical trials. As daily assessment of PROs is becoming common-
place, if not standard in many therapeutic areas, the number of
items within a PRO measure must be considered carefully to
avoid overburdening patients participating in clinical trials and
to minimize missing data. Such pragmatic issues were discussed
more thoroughly in an issue panel conducted in May at the
ISPOR International Meeting by PRO experts employed by a
pharmaceutical company, a consulting ﬁrm, and the National
Cancer Institute [4].
While the FDA/SEALD team’s intent is clearly to protect
consumers, many of us “in the trenches” fear that the hurdle for
PROs, particularly with respect to drug approvals, may be delay-
ing the availability of products in development, as well as dis-
couraging sponsors from developing compounds for which PROs
will be necessary. Nonetheless, I remain optimistic that scientiﬁc
contributions such as the paper written by ISPOR’s PRO Task
Force, well-respected experts in the ﬁeld, and substantiated by
standard psychometric principles will foster further dialog
among all parties involved and ultimately ensure that the hurdle
for the approval of future PRO claims is set at an optimal
level—one that protects patients from false claims while also
facilitating the communication of treatment beneﬁts backed by
scientiﬁcally appropriate evidence.
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